Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders
CBD bears investigation in epilepsy and other neuropsychiatric disorders, including anxiety, schizophrenia, addiction, and neonatal hypoxic‐ischemic encephalopathy, however, data from well‐powered double‐blind randomized, controlled studies on the efficacy of pure CBD for any disorder is lacking.
Pharmacological and biochemical interactions between opioids and cannabinoids.
The endogenous cannabinoid system and brain development
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease
Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine
Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism.
- A. Jaźwa, A. I. Rojo, Nadia G. Innamorato, Marlen Hesse, J. Fernández-Ruiz, A. Cuadrado
- Biology, ChemistryAntioxidants & redox signaling
- 15 June 2011
Results provide strong pharmacokinetic and biochemical evidence for activation of Nrf2 and phase II genes in the brain and also offer a neuroprotective strategy that may have clinical relevance for PD therapy.
Parkinson Phenotype in Aged PINK1-Deficient Mice Is Accompanied by Progressive Mitochondrial Dysfunction in Absence of Neurodegeneration
Older Pink1−/− mice show increasing mitochondrial dysfunction resulting in impaired neural activity similar to PD, in absence of overt neuronal death.
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
- J. Palazuelos, T. Aguado, I. Galve-Roperh
- Biology, ChemistryBrain : a journal of neurology
- 5 October 2009
It is shown that CB(2) cannabinoid receptor expression increases in striatal microglia of Huntington's disease transgenic mouse models and patients, support a pivotal role for CB( 2) receptors in attenuating microglial activation and preventing neurodegeneration that may pave the way to new therapeutic strategies for neuroprotection in Huntington’s disease as well as in other Neurodegenerative disorders with a significant excitotoxic component.
Presence of cannabinoid binding sites in the brain from early postnatal ages.
- F. Rodríguez de Fonseca, J. Ramos, A. Bonnin, J. Fernández-Ruiz
- Biology, PsychologyNeuroreport
- 1 February 1993
The present study demonstrates the presence of cannabinoid receptors in the brain from early postnatal ages, exhibiting a progressive increase which maximised on days 30 or 40 and then subsequently decreased to adult values.